The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease
|Coronary Heart Disease|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||MIF Gene Polymorphism in Coronary Heart Disease：Clinical Meaning|
- Comparison Between Coronary-artery-disease Group and Non-coronary-artery-disease Group on MIF Concentration [ Time Frame: Before surgery 5 minutes ]Participants will be extracted 3ml blood before surgery 5 minutes,detection MIF concentration on two groups.We hypothesis that the experimental group will be higher than control group.
- Comparison the Change of MIF Before and After Percutaneous Coronary Intervention （PCI） at the Patients Who Are Acute Coronary Syndromes and Stable Ischemic Heart Disease [ Time Frame: 3 times including before surgery 5 minutes, 5 minutes after the opening of the balloon and after surgery 5 minutes ]Percutaneous Coronary Intervention are extracted 3 times including before surgery 5 minutes , 5 minutes after the opening of the balloon and after surgery 5 minutes ,and detection MIF concentration .
- Comparison With MIF-173G/C Genotypes of CHD Patients and Controls. [ Time Frame: Before surgery ]
- Comparison of MIF-173G/C Alleles of CHD Patients and Controls. [ Time Frame: Before surgery ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||May 2012|
|Study Completion Date:||November 2013|
|Primary Completion Date:||November 2013 (Final data collection date for primary outcome measure)|
Participants, who are diagnosed as coronary-artery-disease which including acute coronary syndromes and stable ischemic heart disease, will receive at least one stent.
Participants, who are diagnosed as non-coronary-artery-disease without acute coronary syndromes and stable ischemic heart disease, will not receive stent.
MIF is a pleiotropic cytokine that promote the inflammatory response. MIF is expressed in several cell types,including monocytes/macrophages, vascular smooth muscle and cardiomyocytes, and is released on stimulation from pre-formed storage pools. A foreign study reported that MIF had demonstrated to offer protection from I/R-injury by activating adenosine monophosphate-activated protein kinase (AMPK) and inhibiting c-Jun Nterminal kinase (JNK)-induced apoptosis of cardiomyocytes. In addition, animal experiments showed that MIF was reduced in aged heart compared with young heart. Coronary heart disease is a chronic ischemic disease, in which MIF may play as a protective factor during the whole procedure.
We observed individuals who will be taking coronary angiography during the hospitalization. Individuals will be assigned to coronary-artery-disease group, which included acute coronary syndromes and stable ischemic heart disease, or non-coronary-artery-disease group, according to coronary angiography. All participants will be extracted 3ml blood sample 5 minutes before coronary angiography. Coronary-artery-disease group will be taken another two blood samples, 5 minutes after the opening of the balloon and 5 minutes after the stents have been implanted, respectively.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01750502
|Second Hispital of Wenzhou Medical College|
|Wenzhou, Zhejiang, China, 325000|
|Principal Investigator:||Jifei Tang, MD||Wenzhou Medical University|